Ultragenyx Pharmaceutical Overview
Ultragenyx Pharmaceutical Target Price
Analysts' 12-month price predictions for RARE.
Share Price
$36.61
Average Target Price
$89.50
144.5% upside
144.5% upside2 analysts in the last 4 months
High: $115 | Low: $64
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-03-17 | Piper Sandler | $115 | 214.1% upside |  |
| 2025-03-07 | Morgan Stanley | $64 | 74.8% upside | |
| 2024-11-06 | H.C. WainwrightEd Arce | $95 | 159.5% upside | |
| 2024-11-06 | Leerink PartnersJoseph Schwartz | $85 | 132.2% upside | |
| 2024-06-06 | Goldman SachsSalveen Richter | $67 | 83% upside | |
| 2024-05-31 | Stifel NicolausDae Gon Ha | $127 | 246.9% upside | |
| 2024-05-31 | Raymond JamesChristopher Raymond | $135 | 268.8% upside | |
| 2024-05-31 | Robert W. BairdJoel Beatty | $72 | 96.7% upside | |
| 2024-05-31 | Canaccord GenuityWhitney Ijem | $111 | 203.2% upside | |
| 2024-04-15 | Stifel NicolausDae Gon Ha | $124 | 238.7% upside | |
| 2024-04-15 | Raymond JamesChristopher Raymond | $130 | 255.1% upside | |
| 2023-02-03 | Morgan Stanley | $95 | 159.5% upside | |
| 2022-12-30 | H.C. Wainwright | $82 | 124% upside | |
| 2022-07-28 | Piper SandlerChristopher Raymond | $130 | 255.1% upside | |
| 2022-07-01 | Stifel Nicolaus | $142 | 287.9% upside | |
| 2022-05-24 | Goldman Sachs | $101 | 175.9% upside | |
| 2022-05-18 | Piper SandlerChristopher Raymond | $135 | 268.8% upside | |
| 2022-05-06 | Morgan Stanley | $109 | 197.7% upside | |
| 2022-05-06 | Leerink Partners | $115 | 214.1% upside | |
| 2022-01-10 | Cowen & Co.Yaron Werber | $124 | 238.7% upside | |
| 2021-11-03 | CitigroupYigal Nochomovitz | $150 | 309.7% upside | |
| 2021-11-03 | WedbushLaura Chico | $92 | 151.3% upside | |
| 2021-09-27 | Piper SandlerChristopher Raymond | $170 | 364.4% upside | |
| 2021-08-19 | UBSEsther Rajavelu | $73 | 99.4% upside | |
| 2021-08-03 | BarclaysGena Wang | $141 | 285.1% upside | |